Product name

Ipal is offering the use of Agouti for the therapy and prevention of infections

Summary

Use of melanocortin receptor antagonist for the treatment of stroke induced inflammation

Organization name

IPAL GmbH, Charitè University Hospital Berlin

Profile

Agouti is a melanocortin receptor antagonist, which plays a classical role in skin pigmentation and in immune modulation systems.

Agouti depletion provokes acute inflammation in mouse models. The inventors found, that application of agouti in early therapeutic stadium led to lower bacterial load of the lung compared to non treated animals.   

Pneumonia after stroke is one of the most common complications with high possibility of death. Thus agouti can be used for early therapy of stroke associated infections, early therapy of pneumonias and sepsis and general antiinfective prophylaxis in other immunosuppressive diseases induced for example by medication or HIV.

Competitiveness

• Alternative therapeutically strategy to antibiotic approach
• Application is not restricted to infection prevention in stroke patients
• Invention meets an attractive market (stroke as widespread disease and application on other immunosuppressive diseases)

A German patent has been filed. Additional information is provided in the attached pdf. The invention was made at Charité Universitaetsmedizin, Berlin, Germany and is offered by IPAL.

Contact

Dr. Christian Wunsch
christian.wunsch(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitaetsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialpruefung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.        

 

Description File

 06146_Agouti_abstract_01.pdf

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney